4th Targeting Therapy of Alzheimer’s & Related Neurodegenerative Diseases Conference | Fusion Conferences

Early Bird - 19 Nov 2026  â€¢  Talk Submission - 19 Nov 2026  â€¢  Poster Submission - 25 Feb 2027  â€¢  Registration & Payment Deadline - 25 Feb 2027

The hotel is expecting to run at an extremely high occupancy during our conference dates.

Whilst we have a substantial number of rooms reserved for the conference nights, pre / post stays fall outside of our commitment and are subject to availability. Therefore, please finalise your travel plans as soon as possible to enable rooms to be secured well in advance. This is a pre-emptive notice, and we are maintaining regular communication with the hotel to ensure that suitable accommodation can be secured.

Should you wish to extend your stay pre or post-conference, please submit any requests for additional nights to Chloe Trundle so that payment can be arranged and the accommodation secured with the hotel as early as possible.

Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease, affecting nearly 1 in 9 people over 65 in the world. While a great progress in translational and discovery research is excitingly being made, there still lack effective therapies for AD and related neurodegenerative diseases. This planned conference intends to bring together leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees, and to share their vision or prospects on translational or discovery research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets, new genetic association or pathways, approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries to share clinical trial results.